Establishment of an invasive prostate cancer model in transgenic rats by intermittent testosterone administration

Journal of Toxicologic Pathology

Volumn 27, Issue 1, 2014, Pages 43-49

  Sato, Shinya ^a   Suzuki, Shugo ^a   Naiki Ito, Aya ^a   Komiya, Masami ^a,b   Long, Ne ^a,c   Kato, Hiroyuki ^a   Sagawa, Hiroyuki ^a   Yamashita, Yoriko ^a   Shirai, Tomoyuki ^a,d   Takahashi, Satoru ^a  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^c NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^d Nagoya City Rehabilitation Center   (Japan)

Author keywords

Animal model; Cancer invasion; Intermittent administration; Prostate cancer; Testosterone propionate; Transgenic rat

Indexed keywords

2',3 DIMETHYL 4 BIPHENYLAMINE; TESTOSTERONE PROPIONATE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG IMPLANTATION; HISTOPATHOLOGY; INVASIVE CARCINOMA; MALE; NONHUMAN; ORCHIECTOMY; PROSTATE ADENOCARCINOMA; RAT; TRANSGENIC RAT; TUMOR INVASION; TUMOR MODEL;

EID: 84899942347     PISSN: 09149198     EISSN: None     Source Type: Journal    
DOI: 10.1293/tox.2013-0052     Document Type: Article

References (25)

1. Siegel R, Naishadham D, and Jemal A. Cancer statistics, 2013. CA Cancer J Clin. 63: 11-30. 2013. [Medline] [Cross-Ref]
2. Matsuda T, Marugame T, Kamo K, Katanoda K, Ajiki W, and Sobue T. Cancer incidence and incidence rates in Japan in 2006: Based on data from 15 population-based cancer registries in the monitoring of cancer incidence in Japan (MCIJ) project. Jpn J Clin Oncol. 42: 139-147. 2012. [Medline] [CrossRef]
3. Zhang J, Dhakal IB, Zhao Z, and Li L. Trends in mortality from cancers of the breast, colon, prostate, esophagus, and stomach in East Asia: role of nutrition transition. Eur J Cancer Prev. 21: 480-489. 2012. [Medline] [CrossRef]
4. Shirai T, Fukushima S, Ikawa E, Tagawa Y, and Ito N. Induction of prostate carcinoma in situ at high incidence in F344 rats by a combination of 3,2'-dimethyl-4-aminobiphenyl and ethinyl estradiol. Cancer Res. 46: 6423-6426. 1986. [Medline]
5. Shirai T, Tamano S, Kato T, Iwasaki S, Takahashi S, and Ito N. Induction of invasive carcinomas in the accessory sex organs other than the ventral prostate of rats given 3,2'-dimethyl-4-aminobiphenyl and testosterone propionate. Cancer Res. 51: 1264-1269. 1991. [Medline]
6. Asamoto M, Hokaiwado N, Cho YM, Takahashi S, Ikeda Y, Imaida K, and Shirai T. Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent. Cancer Res. 61: 4693-4700. 2001. [Medline]
7. Seeni A, Takahashi S, Takeshita K, Tang M, Sugiura S, Sato SY, and Shirai T. Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac J Cancer Prev. 9: 7-14. 2008. [Medline]
8. Takahashi S, Takeshita K, Seeni A, Sugiura S, Tang M, Sato SY, Kuriyama H, Nakadate M, Abe K, Maeno Y, Nagao M, and Shirai T. Suppression of prostate cancer in a transgenic rat model via gamma-tocopherol activation of caspase signaling. Prostate. 69: 644-651. 2009. [Medline] [CrossRef]
9. Takahashi S, Uemura H, Seeni A, Tang M, Komiya M, Long N, Ishiguro H, Kubota Y, and Shirai T. Therapeutic targeting of angiotensin II receptor type 1 to regulate androgen receptor in prostate cancer. Prostate. 72: 1559-1572. 2012. [Medline] [CrossRef]
10. Long N, Suzuki S, Sato S, Naiki-Ito A, Sakatani K, Shirai T, and Takahashi S. Purple corn color inhibition of prostate carcinogenesis by targeting cell growth pathways. Cancer Sci. 104: 298-303. 2013. [Medline] [CrossRef]
11. Cho YM, Takahashi S, Asamoto M, Suzuki S, Inaguma S, Hokaiwado N, and Shirai T. Age-dependent histopathological findings in the prostate of probasin/SV40 T antigen transgenic rats: lack of influence of carcinogen or testosterone treatment. Cancer Sci. 94: 153-157. 2003. [Medline] [CrossRef]
12. Cho YM, Takahashi S, Asamoto M, Suzuki S, Tang M, and Shirai T. Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model. Prostate Cancer Prostatic Dis. 10: 378-383. 2007. [Medline] [CrossRef]
13. Shirai T, Imaida K, Masui T, Iwasaki S, Mori T, Kato T, and Ito N. Effects of testosterone, dihydrotestosterone and estrogen on 3,2'-dimethyl-4-aminobiphenyl-induced rat prostate carcinogenesis. Int J Cancer. 57: 224-228. 1994. [Medline] [CrossRef]
14. Shirai T, Sano M, Imaida K, Takahashi S, Mori T, and Ito N. Duration dependent induction of invasive prostatic carcinomas with pharmacological dose of testosterone propionate in rats pretreated with 3,2'-dimethyl-4-aminobiphenyl and development of androgen-independent carcinomas after castration. Cancer Lett. 83: 111-116. 1994. [Medline] [CrossRef]
15. Shirai T, Tamano S, Sano M, Imaida K, Hagiwara A, Futakuchi M, Takahashi S, and Hirose M. Site-specific effects of testosterone propionate on the prostate of rat pretreated with 3,2'-dimethyl-4-aminobiphenyl: dose-dependent induction of invasive carcinomas. Jpn J Cancer Res. 86: 645-648. 1995. [Medline] [CrossRef]
16. Cui L, Mori T, Takahashi S, Imaida K, Akagi K, Yada H, Yaono M, and Shirai T. Slight promotion effects of intermittent administration of testosterone propionate and/or diethylstilbestrol on 3,2'-dimethyl-4-aminobiphenyl-initiated rat prostate carcinogenesis. Cancer Lett. 122: 195-199. 1998. [Medline] [CrossRef]
17. Valastyan S, and Weinberg RA. Tumor metastasis: molecular insights and evolving paradigms. Cell. 147: 275-292. 2011. [Medline] [CrossRef]
18. Barron DA, and Rowley DR. The reactive stroma microenvironment and prostate cancer progression. Endocr Relat Cancer. 19: R187-R204. 2012. [Medline] [CrossRef]
19. Otranto M, Sarrazy V, Bonte F, Hinz B, Gabbiani G, and Desmouliere A. The role of the myofibroblast in tumor stroma remodeling. Cell Adh Migr. 6: 203-219. 2012. [Medline] [CrossRef]
20. Orimo A, and Weinberg RA. Heterogeneity of stromal fibroblasts in tumors. Cancer Biol Ther. 6: 618-619. 2007. [Medline] [CrossRef]
21. Webber MM, Trakul N, Thraves PS, Bello-DeOcampo D, Chu WW, Storto PD, Huard TK, Rhim JS, and Williams DE. A human prostatic stromal myofibroblast cell line WPMY-1: a model for stromal-epithelial interactions in prostatic neoplasia. Carcinogenesis. 20: 1185-1192. 1999. [Medline] [CrossRef]
22. Desai KV, and Kondaiah P. Androgen ablation results in differential regulation of transforming growth factor-β isoforms in rat male accessory sex organs and epididymis. J Mol Endocrinol. 24: 253-260. 2000. [Medline] [CrossRef]
23. Sampson N, Koziel R, Zenzmaier C, Bubendorf L, Plas E, Jansen-Durr P, and Berger P. ROS signaling by NOX4 drives fibroblast-to-myofibroblast differentiation in the diseased prostatic stroma. Mol Endocrinol. 25: 503-515. 2011. [Medline] [CrossRef]
24. Kojima Y, Acar A, Eaton EN, Mellody KT, Scheel C, Ben-Porath I, Onder TT, Wang ZC, Richardson AL, Weinberg RA, and Orimo A. Autocrine TGF-β and stromal cellderived factor-1 (SDF-10 signaling drives the evolution of tumor-promoting mammary stromal myofibroblasts. Proc Natl Acad Sci USA. 107: 20009-20014. 2010. [Medline] [CrossRef]
25. Wang J, Ying G, Wang J, Jung Y, Lu J, Zhu J, Pienta KJ, and Taichman RS. Characterization of phosphoglycerate kinase-1 expression of stromal cells derived from tumor microenvironment in prostate cancer progression. Cancer Res. 70: 471-480. 2010. [Medline] [CrossRef]